Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx to Distribute Second Lot of Ampligen® for use in Multiple Indications in Argentina, the United States and Europe

ORLANDO, Fla., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today regulatory inspection and clearance for distribution of the Company’s second...
August 28, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order

ORLANDO, Fla., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that the new Ampligen batch manufactured earlier this year is now released for...
August 24, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

ORLANDO, Fla., Aug. 24, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
August 15, 2018 08:38 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Reports Six Months Ended June 30, 2018 Financial Results and Provides Business Update

OCALA, Fla., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
August 13, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Updates Stockholders, Highlighting Ampligen’s Role in Enhancing Immunotherapeutic Therapies

OCALA, Fla., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in...
July 09, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine

ORLANDO, Fla., July 09, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen®...
July 03, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies

ORLANDO, Fla., July 03, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D company focused on unmet medical needs in immunology, is pleased to...
June 27, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina

ORLANDO, Fla., June 27, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the immediate expansion of its Treatment Protocol/Expanded Access Programs for ME/CFS in...
June 15, 2018 10:19 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot

ORLANDO, Fla., June 15, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the successful completion of the first phase of its Ampligen production plan. The first...
June 05, 2018 11:21 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment

ORLANDO, Fla., June 05, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that its TLR3 agonist Ampligen outperformed two other TLR3 agonists, poly IC and...